Semanteon Capital Management LP Purchases Shares of 56,313 Evolus, Inc. (NASDAQ:EOLS)

Semanteon Capital Management LP acquired a new position in shares of Evolus, Inc. (NASDAQ:EOLS) during the 3rd quarter, Holdings Channel reports. The fund acquired 56,313 shares of the company’s stock, valued at approximately $912,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. California State Teachers Retirement System increased its stake in shares of Evolus by 1.6% during the 1st quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock valued at $674,000 after acquiring an additional 739 shares during the last quarter. ProShare Advisors LLC increased its position in Evolus by 9.9% during the first quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock worth $162,000 after purchasing an additional 1,035 shares during the last quarter. Essex Investment Management Co. LLC raised its stake in Evolus by 0.4% during the third quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company’s stock worth $4,788,000 after purchasing an additional 1,111 shares during the period. Arizona State Retirement System boosted its holdings in shares of Evolus by 9.4% in the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after purchasing an additional 1,253 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Evolus by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock valued at $559,000 after buying an additional 1,637 shares during the period. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Barclays boosted their target price on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research report on Thursday, October 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Friday, September 13th.

Evolus Stock Up 0.6 %

NASDAQ EOLS traded up $0.10 on Monday, hitting $16.56. 25,494 shares of the stock traded hands, compared to its average volume of 581,599. The company has a market capitalization of $1.04 billion, a P/E ratio of -18.09 and a beta of 1.31. The stock has a 50-day moving average of $16.12 and a 200 day moving average of $13.58. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. Evolus, Inc. has a twelve month low of $7.44 and a twelve month high of $17.82.

Evolus (NASDAQ:EOLS) last released its earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million for the quarter, compared to analysts’ expectations of $65.06 million. As a group, analysts expect that Evolus, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Activity

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at approximately $1,305,643.75. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Sandra Beaver sold 3,276 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.96. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.